The Queen’s University of Belfast Confidence in Concept programme 2018/19
Lead Research Organisation:
Queen's University Belfast
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept (CIC) scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions to flexibly support a portfolio of early stage translational research projects. CIC is designed to accelerate the transition from discovery research to viable translational projects by supporting preliminary studies to establish proof-of-concept so that the approach will then become competitive for more substantial translational funding
People |
ORCID iD |
Publications
Cross ER
(2021)
Unravelling the antimicrobial activity of peptide hydrogel systems: current and future perspectives.
in Soft matter
Coulter SM
(2023)
Enzyme-Triggered l-a/d-Peptide Hydrogels as a Long-Acting Injectable Platform for Systemic Delivery of HIV/AIDS Drugs.
in Advanced healthcare materials
| Description | Biomedical Catalysis 2021 R2 - AilseVax: AltRNA8V antigens for cancer vaccines |
| Amount | £365,369 (GBP) |
| Funding ID | 10025636 |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2022 |
| End | 03/2024 |
| Description | Development of vaccine to prevent Pseudomonas aeruginosa infection - North-South Research Programme 2021 |
| Amount | £3,000,000 (GBP) |
| Funding ID | HEA North South 2021 - Strand II - AVACTA via UCD |
| Organisation | Higher Education Authority |
| Sector | Public |
| Country | Ireland |
| Start | 02/2022 |
| End | 01/2026 |
| Description | Innovate UK Innovation Scholar Secondment for ECR Peter Stewart - awarded to Manuel Salto-Tellez |
| Amount | £65,666 (GBP) |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2020 |
| End | 12/2021 |
| Description | Proof of Concept - Long-acting injectable peptide-like hydrogel implant for sustained delivery of HIV drug cabotegravir |
| Amount | £125,827 (GBP) |
| Funding ID | INI POC 1026 - LoO:2111/130282815 |
| Organisation | Invest Northern Ireland |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2021 |
| End | 10/2022 |
| Description | Small molecule inhibitors of the anti-apoptotic FLIP-FADD protein-protein interaction for the treatment of non-small cell lung cancer |
| Amount | £2,693,138 (GBP) |
| Funding ID | 110371/Z/15/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2016 |
| End | 09/2021 |
| Description | Collaborative Agreement - Daniel Longley & Ipsen |
| Organisation | Ipsen |
| Country | Global |
| Sector | Private |
| PI Contribution | Collaboration and licensing agreement between QUB (LOngley, Harrison) and Ipsen for preclinical first in class FLIP inhibitor programme. Underlying work as part of CIC project led to this. The academic team at QUB, led by Professors Dan Longley and Tim Harrison, have developed novel, small molecule FLIP inhibitors and used these to achieve pre-clinical proof of concept, and the priority for the team is now to progress this program towards clinical development. Professor Longley commented "Our work to date strongly supports the potential for FLIP inhibitors as therapeutic agents in multiple oncology settings. Our team is looking forward to partnering with Ipsen's clinical and development experts, harnessing their global knowledge, expertise and networks to advance this program and bring a FLIP inhibitor to people living with cancer around the world." Prof Harrison added "We are excited about the potential of the novel, first in class small molecule FLIP inhibitors we have been able to develop thanks to the support from Wellcome, and now are looking forward to working with Ipsen to move these molecules through the next stages of development, and ultimately into new treatments for patients." |
| Collaborator Contribution | This collaboration and licensing agreement provides Ipsen with a global exclusive licence to research, develop, manufacture, and commercialize FLIP inhibitors. |
| Impact | WO2005053725A3 |
| Start Year | 2021 |
| Description | Use of human ocular specimens |
| Organisation | University of Florida |
| Department | College of Medicine |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Prof Mike Boulton provided expertise and access to clinical samples |
| Impact | Glenn JV, Mahaffy H, Wu K, Smith G, Nagai R, Simpson DA, Boulton ME, Stitt AW. Advanced glycation end product (AGE) accumulation on Bruch's membrane: links to age-related RPE dysfunction. Invest Ophthalmol Vis Sci. 2009 Jan;50(1):441-51. Beattie JR, Pawlak AM, Boulton ME, Zhang J, Monnier VM, McGarvey JJ, Stitt AW. Multiplex analysis of age-related protein and lipid modifications in human Bruch's membrane. FASEB J. 2010 Dec;24(12):4816-24. Glenn JV, Mahaffy H, Dasari S, Oliver M, Chen M, Boulton ME, Xu H, Curry WJ, Stitt AW. Proteomic profiling of human retinal pigment epithelium exposed to an advanced glycation-modified substrate. Graefes Arch Clin Exp Ophthalmol. 2011 Nov 13. [Epub ahead of print] |
| Start Year | 2008 |
| Company Name | AILSEVAX LIMITED |
| Description | New spin out company from QUB and TCD to develop next generation cancer vaccines |
| Year Established | 2021 |
| Impact | N/A |
| Company Name | UNIV8 GENOMICS LTD |
| Description | Univ8 Diagnostics is a spin-out company focusing on developing next-generation diagnostic tests for haematological malignancies. These are based around NGS protocols which offer an advantage over existing PCR-based gold-standard tests |
| Year Established | 2019 |
| Impact | The University and Company successfully secured a UKRI / Innovate UK Innovation Scholar Secondment grant, in order to place an experienced researcher into teh compmany for the purpose of validating these technologies and moving from an academic test into a commercial product |